Embecta reaffirms FY2025 guidance, unveils long-range plan with flat revenue growth, $600M FCF target

Embecta Corp.

Reaffirmed FY2025 guidance: revenue $1.073-1.090B, adjusted EPS $2.70-$2.90, adjusted gross margin 62.75%-63.75%.
Long-range plan (2025-2028): flattish constant currency revenue CAGR, adjusted operating margin ~28%-30%.
Targets ~$600M cumulative free cash flow over LRP; plans to repay $450M-$500M of debt.
Strategic priorities: strengthen core insulin injection business, expand product portfolio, increase financial flexibility through cost savings and debt reduction.
Inaugural Analyst and Investor Day held May 22, 2025, with webcast and presentation materials available online.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.